John ‘Chip’ Scarlett Reveals Rytelo’s Blockbuster Potential at JP Morgan 2025

Our final JP Morgan 2025 video interview was actually recorded after the fact due to an unfortunate equipment malfunction onsite. But chatting with Geron CEO John “Chip” Scarlett after the event’s conclusion did have some advantages, allowing he and editor-in-chief Jonah Comstock to look back on the full week and discuss the mood and some of the trends.

Scarlett also talks in detail about Geron’s work – namely a first-in-class telomerese inhibitor that kills bone marrow cells responsible for lower-risk myelodysplastic syndrome. He explains how the drug, Rytelo, has blockbuster potential, shares some of the successes they’ve already had, and details what will need to go right in the coming year for that to happen.

Check out our final JPM broadcast below for the inside scoop on an up-and-coming pharma company, as well as some thoughts about the JP Morgan conference overall and the current administration in the United States.